Literature DB >> 27771003

Effect of Diffuse Subendocardial Hypoperfusion on Left Ventricular Cavity Size by 13N-Ammonia Perfusion PET in Patients With Hypertrophic Cardiomyopathy.

Hulya Yalçin1, Ines Valenta2, Fatih Yalçin1, Celia Corona-Villalobos2, Nestor Vasquez1, Joshua Ra1, Nagehan Kucukler1, Abdel Tahari2, Iraklis Pozios1, Yun Zhou2, Martin Pomper2, Theodore P Abraham1, Thomas H Schindler2, M Roselle Abraham3.   

Abstract

Vasodilator-induced transient left ventricular (LV) cavity dilation by positron emission tomography (PET) is common in patients with hypertrophic cardiomyopathy (HC). Because most patients with PET-LV cavity dilation lack obstructive epicardial coronary artery disease, we hypothesized that vasodilator-induced subendocardial hypoperfusion resulting from microvascular dysfunction underlies this result. To test this hypothesis, we quantified myocardial blood flow (MBF) (subepicardial, subendocardial, and global MBF) and left ventricular ejection fraction (LVEF) in 104 patients with HC without significant coronary artery disease, using 13NH3-PET. Patients with HC were divided into 2 groups, based on the presence/absence of LV cavity dilation (LVvolumestress/LVvolumerest >1.13). Transient PET-LV cavity dilation was evident in 52% of patients with HC. LV mass, stress left ventricular outflow tract gradient, mitral E/E', late gadolinium enhancement, and prevalence of ischemic ST-T changes after vasodilator were significantly higher in patients with HC with LV cavity dilation. Baseline LVEF was similar in the 2 groups, but LV cavity dilation+ patients had lower stress-LVEF (43 ± 11 vs 53 ± 10; p <0.001), lower stress-MBF in the subendocardial region (1.6 ± 0.7 vs 2.3 ± 1.0 ml/min/g; p <0.001), and greater regional perfusion abnormalities (summed difference score: 7.0 ± 6.1 vs 3.9 ± 4.3; p = 0.004). The transmural perfusion gradient, an indicator of subendocardial perfusion, was similar at rest in the 2 groups. Notably, LV cavity dilation+ patients had lower stress-transmural perfusion gradients (0.85 ± 0.22, LV cavity dilation+ vs 1.09 ± 0.39, LV cavity dilation-; p <0.001), indicating vasodilator-induced subendocardial hypoperfusion. The stress-transmural perfusion gradient, global myocardial flow reserve, and stress-LVEF were associated with LV cavity dilation. In conclusion, diffuse subendocardial hypoperfusion and myocardial ischemia resulting from microvascular dysfunction contribute to development of transient LV cavity dilation in HC. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27771003     DOI: 10.1016/j.amjcard.2016.08.085

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

1.  Stress Myocardial Blood Flow Heterogeneity Is a Positron Emission Tomography Biomarker of Ventricular Arrhythmias in Patients With Hypertrophic Cardiomyopathy.

Authors:  Dai-Yin Lu; Hulya Yalçin; Fatih Yalçin; Min Zhao; Sanjay Sivalokanathan; Ines Valenta; Abdel Tahari; Martin G Pomper; Theodore P Abraham; Thomas H Schindler; M Roselle Abraham
Journal:  Am J Cardiol       Date:  2018-02-06       Impact factor: 2.778

2.  Comparison of two software systems for quantification of myocardial blood flow in patients with hypertrophic cardiomyopathy.

Authors:  Hulya Yalcin; Ines Valenta; Min Zhao; Abdel Tahari; Dai-Yin Lu; Takahiro Higuchi; Fatih Yalcin; Nagehan Kucukler; Yalda Soleimanifard; Yun Zhou; Martin G Pomper; Theodore P Abraham; Ben Tsui; Martin A Lodge; Thomas H Schindler; M Roselle Abraham
Journal:  J Nucl Cardiol       Date:  2018-01-22       Impact factor: 5.952

3.  Coronary microvascular disease in hypertrophic and infiltrative cardiomyopathies.

Authors:  Andreas A Giannopoulos; Ronny R Buechel; Philipp A Kaufmann
Journal:  J Nucl Cardiol       Date:  2022-08-01       Impact factor: 3.872

4.  Coronary microvascular dysfunction in hypertrophic cardiomyopathy detected by Rubidium-82 positron emission tomography and cardiac magnetic resonance imaging.

Authors:  William E Moody; Matthias Schmitt; Parthiban Arumugam
Journal:  J Nucl Cardiol       Date:  2018-03-07       Impact factor: 5.952

5.  EANM procedural guidelines for PET/CT quantitative myocardial perfusion imaging.

Authors:  Roberto Sciagrà; Mark Lubberink; Fabien Hyafil; Antti Saraste; Riemer H J A Slart; Denis Agostini; Carmela Nappi; Panagiotis Georgoulias; Jan Bucerius; Christoph Rischpler; Hein J Verberne
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-11-02       Impact factor: 9.236

6.  Machine Learning Methods for Identifying Atrial Fibrillation Cases and Their Predictors in Patients With Hypertrophic Cardiomyopathy: The HCM-AF-Risk Model.

Authors:  Moumita Bhattacharya; Dai-Yin Lu; Ioannis Ventoulis; Gabriela V Greenland; Hulya Yalcin; Yufan Guan; Joseph E Marine; Jeffrey E Olgin; Stefan L Zimmerman; Theodore P Abraham; M Roselle Abraham; Hagit Shatkay
Journal:  CJC Open       Date:  2021-02-02

7.  Positron emission tomography (15O-water, 11C-acetate, 11C-HED) risk markers and nonsustained ventricular tachycardia in hypertrophic cardiomyopathy.

Authors:  Peter Magnusson; Jonny Nordström; Hendrik J Harms; Mark Lubberink; Fredrik Gadler; Jens Sörensen; Stellan Mörner
Journal:  Int J Cardiol Heart Vasc       Date:  2019-12-20

8.  Emergence of endocardium/epicardium flow gradient as novel risk biomarker in patients with hypertrophic cardiomyopathy.

Authors:  Thomas H Schindler; Ines Valenta; Sudhir Jain
Journal:  Int J Cardiol Heart Vasc       Date:  2020-01-06

9.  Myocardial Perfusion Defects in Hypertrophic Cardiomyopathy Mutation Carriers.

Authors:  Rebecca K Hughes; Claudia Camaioni; João B Augusto; Kristopher Knott; Ellie Quinn; Gabriella Captur; Andreas Seraphim; George Joy; Petros Syrris; Perry M Elliott; Saidi Mohiddin; Peter Kellman; Hui Xue; Luis R Lopes; James C Moon
Journal:  J Am Heart Assoc       Date:  2021-07-27       Impact factor: 5.501

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.